PF PRISM CV Company Profile

✉ Email this page to a colleague

PF PRISM CV has sixteen approved drugs.

There are twenty-nine US patents protecting PF PRISM CV drugs.

There are six hundred and fifteen patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	10,570,202*PED	⤷ Subscribe			Y	⤷ Subscribe
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-002	Sep 7, 2023		RX	Yes	No	8,217,057	⤷ Subscribe		Y		⤷ Subscribe
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018		RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-003	Oct 27, 2017		RX	Yes	No	11,103,497*PED	⤷ Subscribe			Y	⤷ Subscribe
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-001	Sep 4, 2012		RX	Yes	Yes	11,103,497*PED	⤷ Subscribe			Y	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	7,291,347	⤷ Subscribe
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002	5,100,899*PED	⤷ Subscribe
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	8,299,116*PED	⤷ Subscribe
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	5,362,718*PED	⤷ Subscribe
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	8,455,539*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	1 mg and 5 mg	➤ Subscribe	2018-02-23
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	50 mg and 200 mg	➤ Subscribe	2008-04-14
➤ Subscribe	For Injection	50 mg per vial	➤ Subscribe	2009-06-15
➤ Subscribe	Tablets	1 mg and 2 mg	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-release Tablets	50 mg and 100 mg	➤ Subscribe	2012-02-29
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100mg and 500mg	➤ Subscribe	2016-09-06
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2008-09-12
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2010-10-08
➤ Subscribe	Injection	25 mg/mL, 1.8 mL vial	➤ Subscribe	2011-05-25
➤ Subscribe	Tablets	0.5 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Extended-release Tablets	25 mg	➤ Subscribe	2015-05-08

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0440372	SPC/GB02/031	United Kingdom	⤷ Subscribe	PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
1666481	132017000095300	Italy	⤷ Subscribe	PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324
1786785	12/2013	Austria	⤷ Subscribe	PRODUCT NAME: CRIZOTINIB, BEVORZUGT IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, HYDRATS ODER SOLVATS; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
1666481	C 2017 029	Romania	⤷ Subscribe	PRODUCT NAME: TOFACITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREA CITRAT 3-((3R,4R)-4-METIL-3-{METIL-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-AMINO]PERIDINIL)-3-OXO-PROPIONITRIL; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF NATIONAL AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322
1218348	C01218348/01	Switzerland	⤷ Subscribe	FORMER OWNER: AGOURON PHARMACEUTICALS, INC., US
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.